ESLA Stock Overview
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Estrella Immunopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.05 |
52 Week High | US$33.00 |
52 Week Low | US$0.86 |
Beta | 0.12 |
1 Month Change | -14.47% |
3 Month Change | -14.47% |
1 Year Change | -90.16% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -89.21% |
Recent News & Updates
Shareholder Returns
ESLA | US Biotechs | US Market | |
---|---|---|---|
7D | 1.2% | 2.7% | 0.3% |
1Y | -90.2% | 2.9% | 24.2% |
Return vs Industry: ESLA underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: ESLA underperformed the US Market which returned 22.8% over the past year.
Price Volatility
ESLA volatility | |
---|---|
ESLA Average Weekly Movement | 12.6% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ESLA's share price has been volatile over the past 3 months.
Volatility Over Time: ESLA's weekly volatility has decreased from 36% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Cheng Liu | www.estrellabio.com |
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. Fundamentals Summary
ESLA fundamental statistics | |
---|---|
Market cap | US$38.44m |
Earnings (TTM) | -US$8.36m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs ESLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ESLA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.36m |
Earnings | -US$8.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.23 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ESLA perform over the long term?
See historical performance and comparison